摘要
本期孤儿药研发分析报告,汇集了Evaluate Pharma的众多分析数据,从世界金融市场出发,高度洞察2015—2020年间值得期待的孤儿药市场。基于对世界5000强制药和生物技术公司的跟踪分析,重点探讨与解析作为处方药的孤儿药相对于非孤儿药的销售市场趋势、欧美对孤儿药的认定、相关产品和药企的表现、孤儿药Ⅲ期临床研发支出以及投资回报等。
The third edition of EvaluatePharma＇s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world＇s financial markets, into the expected performance of the orphan drag market between 2015 and 2020. Based on EvaluatePharma＇s coverage of over 5000 of the world＇s leading pharmaceutical and biotech companies, the Orphan Drug Report 2015 highlights trends in prescription sales liar orphan vs. non- orphan drugs, orphan designation analysis in the USA and Europe, product and company performance, phase Ⅲ R＆D spend and return on investment.
出处
《药学进展》
CAS
2016年第2期145-155,共11页
Progress in Pharmaceutical Sciences
